Obesity & Endocrinology Research Group, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom.
Obesity & Endocrinology Research Group, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom.
Peptides. 2018 Feb;100:61-67. doi: 10.1016/j.peptides.2017.12.009.
Obesity is a major risk factor for type 2 diabetes and may complicate type 1 diabetes. In parallel with the global epidemic of obesity, the incidence of type 2 diabetes is increasing exponentially. To reverse these alarming trends, weight loss becomes a major therapeutic priority in prevention and treatment of type 2 diabetes. Given that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improve glycaemic control and cause weight loss, they are receiving increasing attention for the treatment of diabetes-obesity. This review discusses current and emerging therapeutic options with GLP-1 RAs and considers the next generation of novel peptide co-agonists with the potential for improved therapeutic outcomes in obesity and type 2 diabetes.
肥胖是 2 型糖尿病的主要危险因素，并且可能使 1 型糖尿病复杂化。随着肥胖的全球流行，2 型糖尿病的发病率呈指数级增长。为了扭转这些令人担忧的趋势，减肥成为预防和治疗 2 型糖尿病的主要治疗重点。鉴于胰高血糖素样肽-1 受体激动剂（GLP-1 RAs）可改善血糖控制并导致体重减轻，因此它们在糖尿病肥胖症的治疗中越来越受到关注。本综述讨论了 GLP-1 RAs 的现有和新兴治疗选择，并考虑了新一代新型肽共激动剂，它们有可能改善肥胖症和 2 型糖尿病的治疗效果。
